Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ori CAR 017 (Primary) ; Cyclophosphamide; Fludarabine; Steroids; Tocilizumab
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Acronyms Oricar-017; POLARIS

    • Most Recent Events

    • 05 Jun 2024 Results presented in the OriCell Therapeutics Media Release.
    • 05 Jun 2024 According to an OriCell Therapeutics media release, long term data from this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 04 Jun 2024 Results (At data cut-off (Jan 16, 2024)presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top